News | July 04, 2023
Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
LG Chem will receive totaling up to $95.5 million for the China rights
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Approval to dramatically change CAR-T therapies landscape
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
